Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Bexarotene Stories

2013-12-17 16:23:22

Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic...

2013-04-24 08:29:56

Previous Research Showed Bexarotene May Have Impact on Biomarkers in the Human Brain NEW YORK, April 24, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and BrightFocus Foundation today announced a funding collaboration that will support a Phase I human clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer's disease. Through this partnership, the organizations are working to address a gap in funding that exists for these...

2013-02-21 08:31:07

WOODCLIFF LAKE, NJ. and MONTREAL, Quebec, Feb. 21, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE: VRX)(TSX: VRX) announced today that Valeant has acquired U.S. rights for Targretin(®) (bexarotene) capsules and Targretin(®) (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones. (Photo:...

2012-12-02 05:01:39

innerQuest Psychiatry is a psychiatrist & psychologist group in Asheville, NC composed of Dr. Leonard Cruz, Dr. Steven Buser and Dr. Richard Smoot. In this article, Dr. Cruz reviews recent evidence of a cancer drug showing hopeful signs for new treatment in Alzheimers disease. Asheville, NC (PRWEB) December 01, 2012 innerQuest Psychiatry is a psychiatrist & psychologist group in Asheville, NC composed of Dr. Leonard Cruz, Dr. Steven Buser and Dr. Richard Smoot. In this article,...

2012-04-02 04:20:02

Tokyo, Apr 2, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Minophagen Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning bexarotene (generic name), a treatment for cutaneous T-cell lymphoma (CTCL).Under the terms of the agreement, Eisai shall grant Minophagen Pharmaceutical the exclusive rights to develop and commercialize bexarotene in Asia, Oceania, the Middle East and Eastern Europe, amongst other regions. However, Eisai retains the right of...

Alzheimer’s Breakthrough: Drug Appeared To Reverse Symptoms In Mouse Trial
2012-02-10 10:23:41

Scientists, long searching for a cure for Alzheimer´s, a reporting a dramatic breakthrough: a drug that quickly reverses the pathological, cognitive and memory deficits in mice afflicted with the disease. The results point to the significant potential that the drug, bexarotene, could help the more than 5 million Americans suffering from the brain disease. However, they cautioned that the study was only used in mice, and that the research needs much more work to determine if the...

2011-04-05 21:20:51

A nutrient found in carrots and sweet potatoes may prove key to fighting breast cancer at early stages, according to a new study by researchers at Fox Chase Cancer Center. Sandra Fernandez, PhD, an assistant research professor at Fox Chase, will present the findings at the AACR 102nd Annual Meeting 2011 on Tuesday, April 5. Retinoic acid, a derivative of vitamin A, could be a promising cancer therapy because it affects cell growth, proliferation, and survival. Although it is being tested in a...

2010-09-07 06:30:00

PHILADELPHIA, Sept. 7 /PRNewswire/ -- TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from...

2009-06-29 07:30:00

Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA,...

c215d278dfa80d1f1156f14f36472add1
2009-06-25 11:45:00

Retinoic acid, a derivative of vitamin A, could lead researchers to a new set of drug targets for treating breast cancer, researchers from the University of Chicago report in the June 25, 2009, issue of the journal Cell.The most common forms of breast cancer are fueled by the female hormone estrogen. By comparing the effects of estrogen and retinoic acid on the entire genome, the researchers found that they have a "yin-yang" effect. They alter the expression of many of the same genes, with...